Co-founded by cognitive neurologist Dr. Étienne de Villers-Sidani (UCSF/McGill University), software engineer Yves Desgagné and neurologist Dr. Paul Giaccomini, INNODEM NEUROSCIENCES is a private company created in 2016 and backed by private investors. The company received FDABreakthrough Device Designation for its ETNA-MS (Eye Tracking Neurological Assessment for Multiple Sclerosis) patented technology and received Health Canada clearance in early Q1-24 for their first product ETNA-MS, offering MS patients a non-invasive digital way to monitor the progression of their disease.
Preliminary clinical trial results have been peer-reviewed and are available in the publication Frontiers of Neurology. The company has already signed partnering agreements with Novartis Pharmaceuticals Canada Inc. including a commercial framework agreement. Other pharmaceutical partnership agreements are in the works and will be announced during the year.
What we do
Innodem Neurosciences is a digital biomarker & AI company that specializes in the development of an eye tracking technology, ETNA™, that shows promising use for neurological assessment of the progression of various neurological diseases. The ETNA™ technology is being trialed with patients living with various neurological diseases, such as multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, Friedreich Ataxia, and cancer-related cognitive impairment.
Social media
Business Type / 業種
R&D / 研究開発Others / その他
Business Domain / 分野
Information technology / ITMedical devices / 医薬機器
Technologies / 技術
Digital Biomarkers / デジタルバイオマーカーPharmacological/Safety evaluation / 薬効・薬理・安全性評価
(ETNA™-MS) is a commercial stage software as a medical device (SaMD), Class II, intended to administer a non-invasive test allowing to track eye-movement metrics in adult patients and to provide MS condition monitoring,
ATNA-AD is the second Innodem product for early diagnosis of Alzheimer Disease. Ongoing development in Canada will allow to file for approval in Q1 2027.